{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T19:12:18Z","timestamp":1723662738302},"reference-count":28,"publisher":"Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Abstract is missing (Short communication)<\/jats:p>","DOI":"10.2340\/actadv.v102.2487","type":"journal-article","created":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T07:48:56Z","timestamp":1651650536000},"page":"adv00722","source":"Crossref","is-referenced-by-count":3,"title":["Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects"],"prefix":"10.2340","volume":"102","author":[{"given":"Jana D.","family":"Albrecht","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Ninosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marthe-Lisa","family":"Schaarschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergij","family":"Goerdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"19022","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127: 2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"19023","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2016-01-643569","DOI":"10.1182\/blood-2016-01-643569"},{"key":"19024","doi-asserted-by":"crossref","unstructured":"Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 479-484.","DOI":"10.1182\/blood-2006-10-054601"},{"key":"19025","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1182\/blood-2006-10-054601","DOI":"10.1182\/blood-2006-10-054601"},{"key":"19026","doi-asserted-by":"crossref","unstructured":"Dobos G, Pohrt A, Ram-Wolff C, Lebbe C, Bouaziz JD, Battistella M, et al. Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients. Cancers (Basel) 2020; 12: 2921.","DOI":"10.3390\/cancers12102921"},{"key":"19027","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/cancers12102921","DOI":"10.3390\/cancers12102921"},{"key":"19028","doi-asserted-by":"crossref","unstructured":"Pulitzer M. Cutaneous T-cell lymphoma. Clin Lab Med 2017; 37: 527-546.","DOI":"10.1016\/j.cll.2017.06.006"},{"key":"19029","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.cll.2017.06.006","DOI":"10.1016\/j.cll.2017.06.006"},{"key":"19030","doi-asserted-by":"crossref","unstructured":"Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, et al. S2k guidelines - cutaneous lymphomas update 2016 - Part 1: classification and diagnosis (ICD10 C82 - C86). J Dtsch Dermatol Ges 2017; 15: 1266-1273.","DOI":"10.1111\/ddg.13372"},{"key":"19031","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.13372","DOI":"10.1111\/ddg.13372"},{"key":"19032","doi-asserted-by":"crossref","unstructured":"Dippel E, Assaf C, Becker JC, von Bergwelt-Baildon M, Beyer M, Cozzio A, et al. S2k guidelines - cutaneous lymphomas update 2016 - Part 2: treatment and follow-up (ICD10 C82 - C86). J Dtsch Dermatol Ges 2018; 16: 112-122.","DOI":"10.1111\/ddg.13401"},{"key":"19033","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/ddg.13401","DOI":"10.1111\/ddg.13401"},{"key":"19034","doi-asserted-by":"crossref","unstructured":"Schiller M, Tsianakas A, Sterry W, Dummer R, Hinke A, Nashan D, et al. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2017; 31: 1841-1847.","DOI":"10.1111\/jdv.14366"},{"key":"19035","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/jdv.14366","DOI":"10.1111\/jdv.14366"},{"key":"19036","doi-asserted-by":"crossref","unstructured":"Husken AC, Tsianakas A, Hensen P, Nashan D, Loquai C, Beissert S, et al. Comparison of pegylated interferon alpha-2b plus psoralen PUVA versus standard interferon alpha-2a plus PUVA in patients with cutaneous T-cell lymphoma. J Eur Acad Dermatol Venereol 2012; 26: 71-78.","DOI":"10.1111\/j.1468-3083.2011.04011.x"},{"key":"19037","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04011.x","DOI":"10.1111\/j.1468-3083.2011.04011.x"},{"key":"19038","doi-asserted-by":"crossref","unstructured":"Harris JM, Martin NE, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40: 539-551.","DOI":"10.2165\/00003088-200140070-00005"},{"key":"19039","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2165\/00003088-200140070-00005","DOI":"10.2165\/00003088-200140070-00005"},{"key":"19040","doi-asserted-by":"crossref","unstructured":"Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis 2003; 23: 23-28.","DOI":"10.1055\/s-2003-41631"},{"key":"19041","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1055\/s-2003-41631","DOI":"10.1055\/s-2003-41631"},{"key":"19042","doi-asserted-by":"crossref","unstructured":"Callizo J, Feltgen N, Pantenburg S, Wolf A, Neubauer AS, Jurklies B, et al. Cardiovascular risk factors in central retinal artery occlusion: results of a prospective and standardized medical examination. Ophthalmology 2015; 122: 1881-1888.","DOI":"10.1016\/j.ophtha.2015.05.044"},{"key":"19043","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ophtha.2015.05.044","DOI":"10.1016\/j.ophtha.2015.05.044"},{"key":"19044","doi-asserted-by":"crossref","unstructured":"Rentiya ZS, Wells M, Bae J, Chen KJ, Chao AN, Turgeon N, et al. Interferon-alpha-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol 2019; 257: 447-452.","DOI":"10.1007\/s00417-018-04209-7"},{"key":"19045","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00417-018-04209-7","DOI":"10.1007\/s00417-018-04209-7"},{"key":"19046","doi-asserted-by":"crossref","unstructured":"d'Alteroche L, Majzoub S, Lecuyer AI, Delplace MP, Bacq Y. Ophthalmologic side effects during alpha-interferon therapy for viral hepatitis. J Hepatol 2006; 44: 56-61.","DOI":"10.1016\/j.jhep.2005.07.026"},{"key":"19047","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jhep.2005.07.026","DOI":"10.1016\/j.jhep.2005.07.026"},{"key":"19048","doi-asserted-by":"crossref","unstructured":"Kunkler AL, Binkley EM, Mantopoulos D, Hendershot AJ, Ohr MP, Kendra KL, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol 2019; 257: 1771-1781.","DOI":"10.1007\/s00417-019-04337-8"},{"key":"19049","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00417-019-04337-8","DOI":"10.1007\/s00417-019-04337-8"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2487\/4366","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2487\/4367","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/2487\/4366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T17:18:34Z","timestamp":1655918314000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/2487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":28,"URL":"https:\/\/doi.org\/10.2340\/actadv.v102.2487","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}